View in EDS PDF Full Text

Quimiorresistencia asociada a enzimas de citocromo P450 en cáncer pulmonar. Revisión descriptiva.

Saved in:
Bibliographic Details
Title: Quimiorresistencia asociada a enzimas de citocromo P450 en cáncer pulmonar. Revisión descriptiva.
Alternate Title: Chemoresistance associated with cytochrome P450 enzymes in lung cancer. Descriptive review.
Authors: Valencia-Cervantes, Jesús1,2 jesvalcer@gmail.com, Sierra-Vargas, Martha Patricia1,3
Source: Revista Biomedica. may2025, Vol. 36 Issue 2, p39-49. 11p.
Subjects: CYTOCHROME P-450, LUNG cancer, DRUG metabolism, DRUG resistance in cancer cells, EPIGENETICS, TREATMENT effectiveness, CELLULAR signal transduction, GENETIC polymorphisms
Abstract (English): Chemoresistance is the main reason for the limited efficacy of cancer therapy. It involves several signaling pathways, such as epigenetic factors, drug transporters, DNA damage repair mechanisms, cell death inhibition, epithelial-mesenchymal transition, and drug metabolism. Cytochrome P450 enzymes are catalytic hemoproteins that metabolize endogenous and exogenous compounds, and their expression influences treatment response. In this descriptive review, we examine the association between the expression or presence of cytochrome P450 enzyme polymorphisms and chemoresistance in lung cancer. A search was performed in PubMed and Science Direct databases using the terms "chemotherapy", "lung cancer" and "CYP450". Ex vivo and in vitro studies of human origin, published in the last 5 years, were included. Review, meta-analysis, and animal model studies were excluded. The search results revealed a total of 173 articles (2020-2024), including three cross-sectional studies involving a total of 179 patients (ex vivo) and two studies with in vitro models, in which the expression or presence of cytochrome P450 enzyme polymorphisms associated with treatment response was evaluated. Selected data describe that expression or polymorphisms of some cytochrome P450 enzyme isoforms, including 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, are involved in chemoresistance in lung cancer. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): La quimiorresistencia es la principal razón de la eficacia limitada de la terapia contra el cáncer e involucra una serie de vías de señalización, como factores epigenéticos, transportadores de fármacos, mecanismos de reparación de daños del ADN, inhibición de la muerte celular, transición epitelio-mesénquima y metabolismo de los fármacos. Las enzimas del citocromo P450 son hemoproteínas catalíticas que metabolizan compuestos endógenos y exógenos, y su expresión influye en la respuesta del tratamiento. En esta revisión descriptiva se examina la asociación entre la expresión o la presencia de polimorfismos de enzimas de citocromo P450 y la quimiorresistencia en cáncer de pulmón. Se realizó una búsqueda en las bases de datos de PubMed y Science Direct utilizando los términos en inglés: "chemotherapy", "lung cancer" y "CYP450". Se incluyeron los estudios ex vivo e in vitro de origen humano, publicados en los últimos 5 años. Fueron excluidos los trabajos de revisión, metaanálisis y de modelos animales. Los resultados de la búsqueda revelaron un total de 173 artículos (2020-2024), incluidos tres estudios transversales que involucraron un total de 179 pacientes (ex vivo) y dos estudios con modelos in vitro, en los que se evaluó la expresión o la presencia de polimorfismos de enzimas de citocromo P450 asociados con la respuesta al tratamiento. La información seleccionada describe que la expresión o los polimorfismos de algunas isoformas de enzimas de citrocromo P450, incluidas 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, participan en la quimiorresistencia en cáncer pulmonar. [ABSTRACT FROM AUTHOR]
Copyright of Revista Biomedica is the property of Centro de Investigaciones Regionales Dr. Hideyo Noguchi; Facultad de Medicina, UADY and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:Chemoresistance is the main reason for the limited efficacy of cancer therapy. It involves several signaling pathways, such as epigenetic factors, drug transporters, DNA damage repair mechanisms, cell death inhibition, epithelial-mesenchymal transition, and drug metabolism. Cytochrome P450 enzymes are catalytic hemoproteins that metabolize endogenous and exogenous compounds, and their expression influences treatment response. In this descriptive review, we examine the association between the expression or presence of cytochrome P450 enzyme polymorphisms and chemoresistance in lung cancer. A search was performed in PubMed and Science Direct databases using the terms "chemotherapy", "lung cancer" and "CYP450". Ex vivo and in vitro studies of human origin, published in the last 5 years, were included. Review, meta-analysis, and animal model studies were excluded. The search results revealed a total of 173 articles (2020-2024), including three cross-sectional studies involving a total of 179 patients (ex vivo) and two studies with in vitro models, in which the expression or presence of cytochrome P450 enzyme polymorphisms associated with treatment response was evaluated. Selected data describe that expression or polymorphisms of some cytochrome P450 enzyme isoforms, including 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, are involved in chemoresistance in lung cancer. [ABSTRACT FROM AUTHOR]
ISSN:0188493X
DOI:10.32776/revbiomed.v36i2.1238